ArticleProtein science : a publication of the Protein Society2025
Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.
Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The hypertrophic cardiomyopathy myosin variant G256E prolongs cardiac muscle relaxation via altered nucleotide handling.Communications chemistry · 2026Article
- What Determines the Directionality of Kinesins? Studying the Anomalous Directionality of Nonclaret Disjunctional Motor Mutants.Journal of the American Chemical Society · 2026Article
- Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease, caused by specific mutations, many of which are encoded by the β-cardiac myosin (MYH7) protein. This work provides molecular insight into the effect of an HCM-causing mutation, R190T of β-cardiac myosin. The Arginine190 (R190) resides near the active site of the cardiac myosin and its alteration by a threonine (T190) residue leads to cardiac abnormalities related to the fatal HCM. Since the mutations lead to change in the function of the myosin, we focused on our previous finding that the motion and its directionality are determined by the rate-determining barrier, which in the current case is the phosphate release step. Our study of the change of the phosphate release barrier used several approaches, including all-atom umbrella sampling simulations, renormalization simulations, binding energy and stability analysis as well as structural and multiple sequence analysis. Our free energy calculations of the barrier for the rate-determining phosphate release step reproduced the observed effect. Furthermore, we show that three key myosin drugs, aficamten, mavacamten, and omecamtiv, modulate the phosphate release barrier of the faulty myosin, and by this means it could repair the defects of the HCM mutant associated with fast phosphate release. In exploring the reasons for the effects of the mutations and the drugs, we conclude that the R190T mutation leads to the destabilization of the prepowerstroke (PPS) state of cardiac myosin. Such destabilization triggers rapid phosphate release from cardiac myosin. Since phosphate release is the rate-determining step of β-cardiac myosin, such alteration of the phosphate release barrier of the R190T mutant is a crucial functional factor. Our study demonstrates the importance of using multiscale approaches for the revelation of key mechanisms of HCM disease. Furthermore, we provide further evidence of the crucial role of the rate-determining barrier in establishing the overall function of the myosin cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.